Background: In prior retrospective studies, we assessed a number of prostate tumor tissue biomarkers that were associated independently with the clinical outcome of men treated with radiotherapy (RT) 6 androgen deprivation therapy (ADT). In this report, the associations of selected biomarkers with biochemical or clinical disease failure (BCDF) were prospectively evaluated in men with T1-T3 prostate cancer on a randomized hypofractionation trial. Methods: Biomarkers were analyzed in 263 of 303 men randomly assigned to standard vs moderate hypofractionation. Median follow-up was 65.9 months. Archival tissue was analyzed for Ki-67 (n ¼ 231), MDM2 (n ¼ 209), p16 (n ¼ 195), Cox-2 (n ¼ 126), p53 (n ¼ 206), bcl2 (n ¼ 223), bax (n ¼ 210), and PKA (n ¼ 160). The base model for multivariable Fine-Gray regression analysis included treatment assignment and risk groups. All statistical tests were two-sided.
A number of diagnostic tissue biomarkers have been related to prostate cancer patient outcome after radiotherapy (1) (2) (3) (4) (5) . Using Radiation Oncology Therapy Group (RTOG) randomized clinical trials as a platform, we found multiple tumor tissue biomarkers of cell kinetics, apoptosis, and angiogenesis to be related to biochemical and/or clinical outcomes of men with prostate cancer treated with external beam radiotherapy (RT), without or with androgen deprivation therapy (ADT). These tumor biomarkers have included Ki-67 (6-10), p53 (11) , MDM2 (7), bcl2&bax (12, 13) , p16 (14) , Cox-2 (15) , and PKA (16, 17) . Virtually all biomarker studies for prostate cancer to date have been retrospective, which could introduce methodological biases. In this report, we prospectively assessed these eight biomarkers using previously established staining procedures and biomarker quantification methods in patients treated on a contemporary randomized hypofractionation trial (18) .
There were 303 assessable patients enrolled in a Fox Chase Cancer Center (FCCC) randomized trial (18) designed to determine whether the equivalent of an 8 Gy dose escalation in standard 2.0 Gy fractions using hypofractionated RT would result in a statistically significant reduction in biochemical or clinical disease failure (BCDF). Patients in the control arm received 76 Gy in 38 fractions, while those in the experimental arm received 70.2 Gy in 2.7 Gy fractions (calculated to be equivalent to 84.4 Gy in 2.0 Gy fractions). No difference in BCDF was seen between the two arms. A secondary aim of the trial was to prospectively determine the relationship of selected biomarkers in diagnostic tissue to BCDF. These results are reported herein.
Methods

Patient Characteristics
Institutional review board approval was obtained at FCCC (18) and later at the University of Miami. With written consent, 303 patients were accrued between 2002 and 2006. Tissue collection, including procuring samples from outside institutions, was finalized in 2007. Sufficient Diagnostic formalin-fixed paraffinembedded tissue was recovered in 263 patients. The staining and analysis of each biomarker was done in batches prospectively and was completed by 2008. The analysis of the association of the biomarker results with the BCDF endpoint was not performed until the median follow-up was over 60 months.
Immunohistochemical Analysis
The immunohistochemical staining protocols for each of the biomarkers have been detailed previously (6, 7, 11, 12, 14, 16, 17) . To summarize, formalin-fixed paraffin-embedded tissue specimens were cut onto poly-L-lysine slides, deparaffinized in xylene, rehydrated, and washed. A pressure cooker was used for antigen retrieval in citrate buffer. Endogenous peroxidase activity was blocked with 3% hydrogen peroxide . The primary antibodies used were MIB-1 for Ki-67 (1:100 Antibody complexes were detected by the labeled streptavidin biotin method (Dako LSAB 2 Kit, Dako) for Ki-67, MDM2, bcl2, bax, p16, Cox-2, and PKA and by the ABC method, using 3-amino-9-ethylcarbazole as the chromogen for p53. Bcl2&bax (12), p53 (11) , and Ki-67 (7) were based on manual scoring, whereas p16 (14), MDM2 (7), and Cox-2 (15) were based on semiautomated image analysis. Positive controls were: Ki-67, normal tonsil (6); MDM2, human prostate carcinoma (7); bcl2, normal prostate; bax, both prostate tissue microarray and human lymph nodes (12) ; PKA, human brain and prostatic carcinoma (17) ; p16, normal prostate epithelium (19) ; Cox-2, adjacent benign prostate epithelium cytoplasmic intensity (14) ; and p53, colon carcinoma with a p53 mutation (7) . Negative controls were produced by omitting the primary antibody.
Image Analysis
Semi-automated image analysis was performed as previously described (20) . The slides were scanned at 10X magnification according to the scanning protocol of the imaging system (ACIS II, Clarient Chromavision Inc., San Juan Capistrano, CA). Digital images were captured by a three-chip CCD camera (Sony, Parkridge, NJ). Color thresholds were then set for each slide to eliminate background. Tumor regions were outlined either with a 40X circular field or by freehand around the glands of interest, thereby excluding stromal tissue and unwanted artifacts. At least six regions of interest were chosen for every case with sufficient tumor. Pixel-based scores representing the percentage of tumor nuclei staining positive (PSP) and the mean intensity score (MIS) were recorded (7, 15) . Additional details on quantification methods and cut-points are given in the Supplementary Materials (available online).
Definition of End Points
The primary end point was the cumulative incidence of BCDF, timed from treatment start to first failure or start of salvage therapy (ADT, cryosurgery, or prostatectomy). Biochemical failure was defined using the nadirþ2 (Phoenix) definition (21) . Clinical failure included local failure (local progression or prostate biopsy proof of disease with a rising prostate-specific antigen [PSA]) or regional/distant metastasis (radiographic or pathologic).
Statistical Analysis
Pretreatment characteristics in the study cohort (n ¼ 263) were compared with those excluded (n ¼ 40) using Fisher's exact test (Table 1 ). Patients were categorized by age, T-category, Gleason score, pretreatment PSA, diagnostic biopsy percent positive tissue (PPT) (22) , and combinations of risk group and planned duration of ADT. The patients were stratified in the original FCCC trial by risk group (18) . The favorable-, intermediate-, and highrisk grouping was based on the American Joint Committee on Cancer (AJCC) 2010 staging manual (23) , and these were further subdivided as follows: favorable (AJCC group I) plus intermediate (AJCC group IIa; termed Fav-Int) risk treated without ADT, intermediate (termed Int) risk treated with short-term ADT (STADT), and high risk (AJCC group IIb or III) treated with longterm ADT (LTADT). We also performed a second multivariable analysis in which the individual risk group covariates and ADT (no ADT, STADT, and LTADT) were included separately.
A multivariable Fine-Gray regression analysis was used to examine associations between biomarkers and BCDF, with death without BCDF considered to be a competing risk (24) . Eight prospectively analyzed biomarkers were considered: Ki-67 (6,7), p53 (11), MDM2 (7), bcl2&bax (12), p16 (14) , Cox-2 (15), and PKA (16, 17) , with each biomarker dichotomized as described previously ( Table 1 ). The single biomarker models were analyzed in order to investigate whether each biomarker was associated with BCDF after adjustment for treatment group and combinations of risk group and planned duration of ADT. Multivariable models were adjusted for variables in the base model, with additional biomarkers selected from the single biomarker models. Cumulative incidence rates were compared using Gray's test statistics (25) .
For internal validation, the cause-specific concordance probability (C-index) in the presence of competing risks was used to evaluate the biomarker models (26) . We assessed predictive performance of the models using the split-sample validation technique (27) . This internal validation approach is widely used, although it is recognized that there are limitations (28) . A bootstrap approach was performed to estimate standard error in the ARTICLE validation data set. We randomly split the data set into training (66.7%) and validation (33.3%) data sets. We used the training data set to estimate the parameters of Fine-Gray regression of both the base and biomarker models. Concordance was estimated using the validation data set. The C-index is a measure to assess the discrimination accuracy of the biomarker model to predict the time-to-event endpoint. We estimated concordance probability of single and grouped biomarkers in multivariable models and compared them with the base model at specific time points. The incremental predictive performance of biomarkers over the base model was assessed using the difference of C-indices between the two models and the corresponding 95% confidence intervals.
All statistical tests were two-sided, and P values of less than .05 were considered statistically significant. Analyses involving competing risks were performed using R-software (http://www. r-project.org) and for all others: SAS (SAS Institute, Cary, NC).
Results
Adequate tissue was available for the immunohistochemical staining of Ki-67 in 231 (76.2%) patients, p53 in 223 (73.6%), bcl2 in 223 (73.6%), bax in 210 (69.3%), MDM2 in 209 (69.0%), p16 in 195 (64.4%), PKA in 160 (52.8%), and Cox-2 in 126 (41.6%). There were 263 patients of the 303 assessable in the protocol that had one or more markers analyzed (main study cohort), and 227 who had four or more of the eight investigated (Table 1) . There were no differences between the group that had four or more markers and the other patients in terms of the clinical-pathologic covariates listed.
A base multivariable Fine-Gray regression model was created (Table 2 ) using the covariates of treatment arm, Fav-Int risk without ADT, Int riskþSTADT (median length ¼ 4 months), and high riskþLTADT (median length ¼ 24 months). The end point was BCDF, including the nadirþ2 definition of biochemical failure. There were 47 failures, three competing risk deaths, and 213 failure-free survivors in this cohort. This model was chosen and tested in the prior publication describing the primary end point (18) because it was based on stratification criteria. There were no statistically significant covariates in the base model, in both the entire cohort (18) and the biomarker cohort studied herein.
We tested each of the biomarkers, one at a time, with the base model covariates. The cut-points for each biomarker were previously established and reported. Of the eight biomarkers tested, Ki-67 was the most statistically significant at the preestablished cut-point (hazard ratio [ Figure 1 , available online) (29) . The locally weighted scatterplot smoothing (LOWESS) line showed no trend along the Ki-67 values, satisfying the linearity assumption. The combination of abnormal/altered bcl2&bax expression was statistically significant (HR ¼ 2.19, 95% CI ¼ 1.08 to 4.46 P ¼ .03) and had a higher hazard ratio than bcl2 intensity (HR ¼ 1.85, 95% CI ¼ 0.99 to 3.45, P ¼ .05). We tested whether the statistically significant biomarkers were predictive of treatment (30) . The interaction with treatment (random assignment arm) was not statistically significant (P ¼ .13 for Ki-67; P ¼ .70 for bcl2&bax).
Since the base model was founded on protocol stratification covariates and the biomarker cohort is a subgroup, we also tested each marker one at a time with a modified base model comprised of the covariates of T-stage, Gleason score, PSA, and length of ADT (modified base model, Supplementary Table 1, available online). Overall, the results were similar for Ki-67 (HR ¼ 2.13, 95% CI ¼ 1.07 to 4.25, P ¼ .03) but were less consistent for bcl2&bax (HR ¼ 1.90, 95% CI ¼ 0.91 to 3.97, P ¼ .09), with statistical significance seen for bcl2 intensity instead (HR ¼ 1.89, 95% CI ¼ 1.03 to 3. 47, P ¼ .04). In the modified multivariable analyses, Ki-67 maintained statistical significance, while bcl2&bax did not.
When Ki-67 at the 11.3% cut-point and abnormal bcl2&bax expression were included with the base model covariates in multivariable analysis (Table 2) , both maintained statistical significance. Figure 1A displays the cumulative incidence of BCDF adjusted for the competing risk of death without BCDF, subdivided by Ki-67 > 11.3% and 11.3%, with five-year rates of 28.7% and 14.4%. Figure 1B shows BCDF cumulative incidence by bcl2&bax, with 31.5% for abnormal/altered and 14.4% for other bcl2&bax combinations at five years.
As Ki-67 and bcl2&bax were independently predictive of BCDF, we merged them and the four resultant groups were examined ( Figure 1C) . The five-year BCDF rates were 50% for Ki-67 > 11.3% and bcl2&bax abnormal/altered, 21.1% for Ki-67 > 11.3% and bcl2&bax other, 20.3% for Ki-67 11.3% and bcl2&bax abnormal/ altered, and 13.4% for Ki-67 11.3% and bcl2&bax other (overall P ¼ .003, Gray's test). We then pooled the two middle groups because 
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the BCDF cumulative incidence curves were superimposable ( Figure 1D ). In multivariable analysis of the merged Ki-67 and bcl2&bax data with three groups (Table 2) , the high Ki-67 and abnormal bcl2/altered bax group (n ¼ 14) had a statistically significantly worse outcome (HR ¼ 5.37, 95% CI ¼ 1.87 to 15.5, P ¼ .002) as compared with "low Ki-67 & Other bcl2&bax." Time-dependent C-index analyses were performed to gain insight into the clinical relevance of the biomarker findings. Estimated six-month interval C-index values for the biomarker and base models for years 1 through 6 after radiotherapy are displayed in Figure 2 . There were 231 assessable Ki-67 patients randomly divided into a training data set with 154 (66.7%) who had 27 BCDFs and a validation data set with 77 (33.3%) who had 14 BCDFs. There were 186 assessable Ki-67 and bcl2&bax merged patients divided into a training set of 123 with 23 BCDFs and a validation set of 63 who had 12 BCDFs. The training data set was used to estimate the parameters of the Fine-Gray regression model for both the base and biomarker models. Causespecific concordance indices for BCDF were estimated using the validation data sets. The biomarker models showed better discriminative performance (higher C-indices) compared with the base model. The base models vary slightly because of differences in the numbers of assessable patients (Table 3 ). The greatest increases in the C-indices relative to the base model were seen for Ki-67 alone, with stabilization at year 2 and beyond. The values and differences over those of the base model are enumerated in Table 3 , which demonstrates that most of these differences were statistically significant. However, for both the bcl2&bax only and merged models, the C-indices at 1.5 years and beyond were not statistically different from those of the base model. The data suggest that the addition of Ki-67 to the base model resulted in the most clinically meaningful model, although the addition of bcl2&bax to the Ki-67 and base models reduced the number of assessable patients and the power of the observations. We also computed time-dependent areas under receiver operating characteristic curves (ROC) (31) using Ki-67 as a continuous covariate in the model between two and five years ( Figure 2D) . The values of the areas under the ROC curves ranged between 81.0% and 66.4%.
Discussion
We describe a prospective prostate tumor tissue biomarker analysis based on immunohistochemical quantification of 
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proteins from pathways related to the cell cycle, angiogenesis, and apoptosis that were previously established to be associated with prostate cancer outcome after RT 6 ADT. The biomarkers and cut-points were predetermined from prior phase III RTOG clinical trials 86-10 (8,20,32) and 92-02 (6, 7, 14) analyses. Our objective was to confirm the statistical significance of these biomarkers from tissue collected and analyzed prospectively. To our knowledge, this is the first such prospective biomarker analysis in men treated with prostate cancer radiotherapy. The prospective cohort was from a phase III FCCC hypofractionation clinical trial (18) that was initiated in 2002 and completed accrual in 2006. The primary endpoint of the trial was BCDF, which is driven in this analysis by biochemical failure using the nadirþ2 definition (21) . This definition is strongly associated with eventual clinical failure, metastasis, and mortality (33) . As expected, there were insufficient metastatic events or deaths with a median follow-up 65.9 months to assess these endpoints; there were only three patients with metastases and four deaths due to prostate cancer.
Of the eight biomarkers examined herein, Ki-67 and the bcl2&bax combination were statistically significant when tested one at a time and in combined testing in multivariable analyses along with treatment arm, risk group, and use of ADT (base model). The randomized trial was designed with risk-stratified treatment wherein more intensified treatment (longer ADT) was used in high-risk patients, shorter ADT in more unfavorable intermediate-risk patients, and no ADT in favorable-to favorable/intermediate-risk patients. While the base model included random assignment arm (not statistically significant in parent cohort [18] ) and risk/ADT groups, none of these factors were statistically significantly associated with BCDF, likely because of such treatment adjustments by risk. Thus, the most statistically significant covariates identified were Ki-67 and the bcl2&bax combination. When these identified biomarkers were included in the multivariable model together (Table 2) , they continued to be independently predictive of BCDF. Because both were independently statistically significant, we merged the Ki-67 and bcl2&bax into three groups that had low, intermediate, and high probabilities of BCDF and reran the multivariable analysis (MVA). The only statistically significant group was comprised of the 14 high-probability patients (7.5% of the merged MVA cohort); the intermediate-probability group did not reach statistical significance, perhaps related in part to power limitations.
Our study is not without limitations. Power limitations, the risk-stratified treatment approach, and the BCDF end point could also have had a role in the inability to establish that others of the tested biomarkers were related to outcome after RT 6 ADT. All had been previously reported by our group to be statistically significantly correlated with prostate cancer patient outcome, especially using distant metastasis as the endpoint. A recent analysis of seven biomarkers from RTOG 92-02 resulted in a distant metastasis model that, after biomarker selection, incorporated Ki-67, MDM2, Cox-2, and p16, in addition to clinical, pathologic, and treatment covariates (34) . The bcl2&bax combination was specifically tested, but was not selected for inclusion in the final model. The difference between that study and the current one includes that BCDF more reflects biochemical failure and the prospective assessment of bcl2&bax may have resulted in better capture of the abnormalities being measured by reducing the potential for degradation.
Time-dependent C-index analyses were used to evaluate gains in the accuracy of discrimination to predict BCDF from the biomarker models over the baseline model. The model with the greatest relative gain was using Ki-67 as the only biomarker. The bcl2&bax biomarker model consistently had a higher Cindex than the base model, but at a much lower level. The merged biomarker model also was not as robust as the Ki-67 only model because of the smaller number of patients in the validation data set.
In conclusion, Ki-67 has repeatedly been related to patient outcome in those with prostate cancer (5), as well as other malignancies (35) . Ki-67 is a measure of growth fraction (36) . Recent reports in prostate cancer indicate that high Ki-67 indices are associated with the basal cell phenotype (37) , which in breast cancer has the most aggressive behavior (high average Ki-67 indices of about 50%) (38) , as compared with the luminal phenotypes. In this prospective biomarker analysis using a primarily biochemical endpoint, Ki-67 at the previously established cut-point of 11.3% was the most statistically significant covariate with the most consistently statistically significant C-index increases over the base model. The availability and simplicity of adding percent Ki-67 nuclear staining to clinicalpathologic criteria makes it more amenable for immediate application. While the 11.3% cut-point was validated in this report, the 10% cut-point is routinely reported by clinical laboratories. Using a 10% cut-point provides a similar measure of prognosis (eg, five-year BCDF of 29.0% for Ki-67 > 10% vs 13.3% for 10%) and when more aggressive treatment should be considered. 
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